| August 12, 2008 |
NVENTA BIOPHARMACEUTICALS CORPORATION
ANNOUNCES SECOND QUARTER 2008 FINANCIAL RESULTS AND RECENT CORPORATE
HIGHLIGHTS
[ Read
more ]
Download
a PDF file of this release
|
| July 29, 2008 |
NVENTA WINS EUROPEAN PATENT CHALLENGE
COVERING LEAD PRODUCT CANDIDATE HSPE7 AND OTHER HPV THERAPEUTICS
[ Read
more ]
Download
a PDF file of this release
|
| July 28, 2008 |
NVENTA ANNOUNCES FINAL DATA FROM HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
-- Company Provides Update to Phase 2 Development Plan --
[ Read
more ]
Download
a PDF file of this release
|
| June 18, 2008 |
NVENTA DEVELOPS PROPRIETARY VACCINE ADJUVANT
Potent Adjuvant is a Toll-Like Receptor 3 (Tlr3) Agonist
[ Read
more ]
Download
a PDF file of this release
|
| June 16, 2008 |
NVENTA TO PRESENT AT BIO 2008 INTERNATIONAL
CONVENTION
[ Read
more ]
Download
a PDF file of this release
|
| May 28, 2008 |
NVENTA APPOINTS GORDON H. BUSENBARK
TO BOARD OF DIRECTORS
[ Read more ]
Download a PDF file
of this release
|
| May 13, 2008 |
NVENTA BIOPHARMACEUTICALS CORPORATION ANNOUNCES
FIRST QUARTER 2008 FINANCIAL RESULTS
[ Read
more ]
Download a PDF file of this release
|
| May 12, 2008 |
NVENTA ANNOUNCES ADDITIONAL POSITIVE
IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
All Patients in Cohort 3 Demonstrated Improvement
in T-Cell Responses Further Supporting the Therapeutic Potential
of HspE7
[ Read
more ]
Download a PDF file of this release
|
| May 7, 2008 |
NVENTA APPOINTS JOHN VARIAN TO BOARD
OF DIRECTORS
-- New Member Complements Board With Significant Financial
and Operational Expertise --
[ Read
more ]
Download a PDF file of this release
|
| April 24, 2008 |
NVENTA COMPLETES SAFETY EVALUATION
ON FINAL COHORT IN HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
-- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin
Mid-2008 --
[ Read
more ]
Download
a PDF file of this release
|
| March 26, 2008 |
NVENTA ANNOUNCES POSITIVE INTERIM
IMMUNOLOGICAL DATA FROM
HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
3 out of 4 Patients in Cohort 2 Demonstrate T-Cell
Responses
Indicating Potential HspE7 Therapeutic Benefit
[ Read
more ]
Download
a PDF file of this release
|
| March 13, 2008 |
NVENTA BIOPHARMACEUTICALS REPORTS
FULL YEAR 2007 AND
FOURTH QUARTER FINANCIAL RESULTS
-- Company Advancing Lead Candidate HspE7 into Phase 2 Clinical
Trial in 2008 --
[ Read
more ]
Download
a PDF file of this release
|
| March 11, 2008 |
NVENTA ENROLLS AND INITIATES DOSING
OF FINAL COHORT IN
HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
[ Read
more ]
Download
a PDF file of this release
|
| March 3, 2008 |
NVENTA EVALUATION COMPLETE FOR FIRST
THREE COHORTS IN HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
-- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly
--
[ Read
more ]
Download
a PDF file of this release
|
| January 23, 2008 |
NVENTA CONCLUDES ENROLLMENT AND INITIAL
DOSING OF THIRD COHORT IN HSPE7 PHASE 1 CERVICAL DYSPLASIA
TRIAL
[ Read
more ]
Download
a PDF file of this release
|
| January 14, 2008 |
NVENTA COMPLETES EVALUATION OF SECOND
COHORT IN HSPE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
[ Read
more ]
Download
a PDF file of this release
|
| |
